Meltwind Advisory
VC Fund
Cambridge, United Kingdom
Meltwind Advisory is a VC fund in Cambridge focused on Biotechnology and Health Care. Meltwind Advisory.
- Total investments:
- 32
- Last investment:
- Lead investor:
- 13%
Last updated:
For AI agents: llms.txt
Industries Meltwind Advisory invests in
Stages Meltwind Advisory invests in
Countries Meltwind Advisory invests in
Round sizes
Round size
- Seed
- $1.2M–$16M
- Pre-Seed
- $996k–$2.5M
- Series A
- $2.9M–$94M
Investment Focus
Industry
- Biotechnology 18 (56%)
- Health Care 12 (38%)
- Therapeutics 7 (22%)
- Medical 6 (19%)
- Pharmaceutical 6 (19%)
Stage
- Seed 14 (44%)
- Series A 7 (22%)
- Pre-Seed 4 (13%)
- Funding Round 2 (6%)
- Series B 1 (3%)
Country
- United Kingdom 23 (72%)
- United States 3 (9%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Qureight
|
Qureight is an imaging analytics company. It also aims to develop a new improved and streamlined version of its analytical platform – harnessing the ability of AI and advanced processing tools to gain new insights into respiratory diseases such as Idiopathic Pulmonary Fibrosis (IPF) and lung cancer. | $20M / Series B / Jul 29, 2026 | |
IMU Biosciences
|
IMU is a discovery engine mapping the immune system to advance precision medicine. | $38.4M / Series A / Jun 01, 2026 | |
Syndex Bio
|
Syndex Bio is a biotechnology platform offering molecular technologies and AI for the diagnosis and treatment of disease. | $15.5M / Seed / Feb 23, 2026 | |
Trogenix
|
Trogenix operates as a therapeutics company, that treats aggressive cancers. | $94.4M / Series A / Oct 06, 2025 | |
Enhanc3D Genomics
|
Enhanc3D Genomics is a spinout company from Babraham Institute. | $5.4M / Series A / Sep 16, 2025 | |
Natrox
|
Inotec AMD is a wound-care company that has developed Natrox:tm:, a device that produces a continuous flow of humidified oxygen and directs it to a specially-designed dressing, allowing oxygen to constantly refresh the wound.NATROX:tm: is a battery-powered medical device that produces a continuous flow of pure humidified oxygen from air anddirects it through a fine tube to a specially-designed Oxygen Delivery System (ODS), allowing the oxygen to constantly refresh the wound while allowing free passage of wound fluids (exudate) to pass away from the wound surface for absorption and retention in the normal way. | $33M / Series C / Dec 02, 2024 | |
Shift Bioscience
|
Shift Bioscience is using simulation guided cell rejuvenation to defeat the diseases of aging. Cellular reprogramming with Yamanaka factors can reverse aging in the dish but is not yet safe for clinical use. Shift has pioneered the first high-throughput, high-accuracy aging biomarker, which has been leveraged inside AI-based cell simulations toidentify safer rejuvenation gene-factors. Shift envisions the development of a single drug-family that can treat multiple diseases of aging, after which full and continued health into old age becomes accessible by simple prescription. | $16.3M / Seed / Oct 15, 2024 | |
NanoSyrinx
|
NanoSyrinx is an emerging biotechnology company developing a novel system for targeted delivery of therapeutic proteins and peptides direct to the cytosol. We are using synthetic biology approaches to develop a completely novel method for targeted drug delivery of therapeutic proteins and peptides, to the interiors of cells, to improve efficacy,safety, and economy. | $13.1M / Series A / Sep 10, 2024 | |
Infinitopes
|
Infinitopes is a cancer research organization whose mission is to strengthen the immune system so that it can stop metastases and save lives. The company's platform creates healthcare systems and therapy designs to integrate high-efficiency vector delivery systems with optimal tumor target identification technologies in early-stage clinicaltrials, allowing patients to prevent cancer and tumors from taking their lives | $16M / Seed / Apr 30, 2024 | |
|
Qureight
|
Qureight is an imaging analytics company. It also aims to develop a new improved and streamlined version of its analytical platform – harnessing the ability of AI and advanced processing tools to gain new insights into respiratory diseases such as Idiopathic Pulmonary Fibrosis (IPF) and lung cancer. | $8.5M / Series A / Apr 16, 2024 | |
| See all 32 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Meltwind Advisory invest in?
Meltwind Advisory invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Seed and Series A stage. Most of the 32 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Meltwind Advisory's check size?
Meltwind Advisory typically joins rounds of $1.2M–$16M at Seed, $996k–$2.5M at Pre-Seed and $2.9M–$94M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Meltwind Advisory participates in.
When did Meltwind Advisory last invest?
The most recent investment recorded for Meltwind Advisory closed in Jul 2026. Shizune tracks 32 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
